A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks

Systemic sclerosis (SSc) is a rare autoimmune disease in which many patients experienceRaynaud's phenomenon (RP) ‐ painful episodes where commonly fingers or toes change colorand become painful, numb, or tingly, usually triggered by cold or stress. This open‐labelstudy is testing an inhaled powder form of treprostinil (LIQ861) to find out which dosescan be taken safely and comfortably by adults with SSc who have frequent symptomatic RPattacks. About 75 adults will be randomly assigned (2 to 1) to either a dose‐titrationgroup or a fixed low‐dose group. The study also explores whether treatment reduces thenumber, severity, and impact of RP attacks. The main goal is to identify tolerateddose(s).